Committed to Helping You Get Your Genentech Medicine
Knowing what to expect can make all the difference. We can help you
through each step of getting your Genentech medicine.
Frequently Asked Questions
About KADCYLA Access Solutions
What is KADCYLA Access Solutions?
KADCYLA Access Solutions is a resource for people who take a
Genentech medicine. We connect you to the medicine you need.
I Am Concerned About Paying for KADCYLA
My co-pays for KADCYLA are too high. How can you help me?
There may be options to help you get the Genentech medicine your doctor has prescribed. KADCYLA Access Solutions can refer you to patient assistance options.
Getting My Medicine
How long will it take to get my medicine?
You might not be able to get your Genentech medicine right away.
First, your doctor’s office or specialty pharmacy will have to check
to make sure your health insurance plan covers your medicine. This is
called a “benefits investigation.” They also might have to send some
more information before your plan covers your medicine. This is called
a “prior authorization.”
Enrolling in KADCYLA Access Solutions
How do I enroll in KADCYLA Access Solutions?
- You fill out a form called the PAN.
- Your doctor fills out a form called the SMN. You do not have to fill out anything on this form.
- Your doctor sends both of these forms to KADCYLA Access Solutions.
There are 2 ways to fill out the PAN form:
- You can fill out the form online
- You can download and print it to fill out a paper copy
Why do I need to sign the PAN form?
The PAN form lets us discuss your health information with your doctor
and your health insurance plan. We can’t work with you without a
I submitted the PAN online or gave the signed PAN to my doctor. Is there anything else I need to do to enroll?
You do not need to do anything else, but your doctor does. He or she needs to submit a form called the SMN. The SMN tells us your doctor wants to treat you with KADCYLA. Make sure your doctor has sent us the SMN so you get help from us.
You do not need to fill out anything on the SMN form.
My Health Plan Denied Coverage for KADCYLA
My health insurance plan will not cover KADCYLA. What do I do?
If your health insurance plan will not cover your Genentech medicine,
you and your doctor’s office can file an appeal. Contact your doctor
to ask if you should file an appeal.
We have resources to help you and your doctor file an appeal.
Does KADCYLA Access Solutions send the appeal to my health insurance care plan?
We have resources to help you and your doctor file an appeal. You or
your doctor’s office has to file the appeal directly with your health
How long does an appeal take?
This depends on your health insurance plan. You should ask your plan directly about its process. Sometimes the appeals process is quick. However, it can take several months if you have to appeal several times.
My Insurance Might Change
I am enrolled in KADCYLA Access Solutions and my health insurance plan has changed. What do I do next?
If your insurance changes while you’re taking your Genentech
medicine, call us. We can help you understand your new coverage.
I no longer have a health insurance plan. What should I do?
GATCF helps people who don't have health insurance. It also helps
people who have health insurance but have trouble paying for their
Genentech medicine. If you qualify for GATCF, you could receive your
medicine for free.
It is your and your doctor's responsibility to complete and submit
all required paperwork to your health insurance plan. Genentech
cannot guarantee your plan will cover any treatments.
PAN=Patient Authorization and Notice of Request
for Transmission of Health Information to Genentech Access Solutions
and Genentech® Access to Care Foundation.
SMN=Statement of Medical Necessity.
Important Safety Information & Indication
What it Treats
KADCYLA is approved to treat HER2-positive breast cancer that has spread to other parts of the body (metastatic breast cancer) after prior treatment with trastuzumab (Herceptin) and a taxane. Prior treatment could have been for the initial treatment of breast cancer or for the treatment of cancer that had spread to other parts of the body.
Important Safety Information
What is the most important safety information I should know about KADCYLA?
KADCYLA is not the same medicine as trastuzumab (Herceptin).
- KADCYLA may cause severe liver problems that can be life-threatening. Symptoms of liver problems may include vomiting, nausea, eating disorder (anorexia), yellowing of the skin (jaundice), stomach pain, dark urine, or itching
- KADCYLA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure). Symptoms may include swelling of the ankles or legs, shortness of breath, cough, rapid weight gain of greater than 5 lb in less than 24 hours, dizziness or loss of consciousness, or irregular heartbeat
- Receiving KADCYLA during pregnancy can result in the death of an unborn baby and birth defects. Birth control should be used while you receive KADCYLA and for 7 months after your last dose of KADCYLA
- If you are exposed to KADCYLA during pregnancy or become pregnant within 7 months of your last dose of KADCYLA, contact your healthcare provider right away; you are also encouraged to enroll in the MotHER Pregnancy Registry by calling 1-800-690-6720 or visiting http://www.motherpregnancyregistry.com/
- You are also encouraged to report exposure to KADCYLA during pregnancy, or if you become pregnant within 7 months of your last dose to Genentech by calling 1-888-835-2555
- If you are a mother who is breastfeeding, you should talk with your doctor about either stopping breastfeeding or stopping KADCYLA
Contact your doctor right away if you experience symptoms associated with these side effects.
What are the additional possible serious side effects of KADCYLA?
- KADCYLA may cause lung problems, including inflammation of the lung tissue, which can be life- threatening. Signs of lung problems may include trouble breathing, cough, tiredness, and fluid in the lungs
- Symptoms of an infusion-related reaction may include one or more of the following: the skin getting hot or red (flushing), chills, fever, trouble breathing, low blood pressure, wheezing, tightening of the muscles in the chest around the airways, or a fast heartbeat. Your doctor will monitor you for infusion-related reactions
- KADCYLA can cause life-threatening bleeding. Taking KADCYLA with other medications used to thin your blood (antiplatelet) or prevent blood clots (anticoagulation) can increase your risk of bleeding. Your doctor should provide additional monitoring if you are taking one of these other drugs while on KADCYLA. Life-threatening bleeding may also happen with KADCYLA, even when blood thinners are not also being taken
Low Platelet Count
- Low platelet count may happen during treatment with KADCYLA. Platelets help your blood to clot. Signs of low platelets may include easy bruising, bleeding, and prolonged bleeding from cuts. In mild cases there may not be any symptoms
- Symptoms may include numbness and tingling, burning or sharp pain, sensitivity to touch, lack of coordination, muscle weakness, or loss of muscle function
Skin Reactions Around the Infusion Site
- KADCYLA may leak from the vein or needle and cause reactions such as redness, tenderness, skin irritation, or pain or swelling at the infusion site. If this happens, it is more likely to happen within 24 hours of the infusion
How will my doctor know if KADCYLA is right for me?
You must have a HER2 test to determine if your cancer is HER2-positive before taking KADCYLA, because benefit has been shown only in patients whose tumors are HER2-positive.
What are the most common side effects of KADCYLA?
The most common side effects seen in people taking KADCYLA are:
- Pain that affects the bones, muscles, ligaments, and tendons
- Low platelet count
- Liver problems
You are encouraged to report side effects to Genentech and the FDA. You may contact Genentech by calling 1-888-835-2555. You may contact the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.
Please see the full Prescribing Information for additional Important Safety Information, including most serious side effects, at www.kadcyla.com.